We are live on ! Find out more
PACB icon

Pacific Biosciences

2.90 USD
+0.07
2.47%
At close Updated Oct 29, 4:00 PM EDT
Pre-market
After hours
2.79
-0.11
3.79%
1 day
2.47%
5 days
43.56%
1 month
58.47%
3 months
107.14%
6 months
97.28%
Year to date
57.61%
1 year
44.28%
5 years
-89.05%
10 years
-65.88%
 

About: Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Employees: 485

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 22.6%
Neutral 58.1%
Negative 19.4%
Neutral
Zacks Investment Research
13 hours ago
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
In the latest trading session, Pacific Biosciences of California (PACB) closed at $2.9, marking a +2.47% move from the previous day.
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
Neutral
GlobeNewsWire
2 days ago
PacBio to Participate in Upcoming Investor Conferences
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences:
PacBio to Participate in Upcoming Investor Conferences
Negative
Zacks Investment Research
2 days ago
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
PACB's growing clinical adoption, advanced sequencing technologies and rising consumables sales support growth, but funding headwinds and margin pressures persist.
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
Neutral
Zacks Investment Research
7 days ago
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.06, representing a -3.74% change from its previous close.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Neutral
GlobeNewsWire
10 days ago
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows Verily Pre will connect PacBio HiFi Sequencing with governed cloud analysis, multimodal health data and AI-ready research workflows
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Neutral
Zacks Investment Research
15 days ago
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $1.99, indicating a -2.93% shift from the previous trading day.
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Neutral
GlobeNewsWire
15 days ago
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2026 financial results on Wednesday, November 4, 2026, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
Positive
Zacks Investment Research
16 days ago
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
PACB partners with TychoBio to harness AI and long-read RNA sequencing for rare disease therapies, aiming to improve drug efficacy and safety through advanced data models.
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
Neutral
Zacks Investment Research
21 days ago
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
The latest trading day saw Pacific Biosciences of California (PACB) settling at $2.3, representing a -15.44% change from its previous close.
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
Neutral
GlobeNewsWire
23 days ago
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models PacBio Kinnex sequencing will generate full-length transcript data to help advance TychoBio's drug discovery models
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
Price charts implemented using Lightweight Charts™